Inhibition of farnesyl pyrophosphate synthase attenuates high glucose‑induced vascular smooth muscle cells proliferation

Chen,Guo‑Ping; Zhang,Xiao‑Qin; Wu,Tao; Han,Jie; Ye,Dan

doi:10.3892/mmr.2017.6360

Inhibition of farnesyl pyrophosphate synthase attenuates high glucose‑induced vascular smooth muscle cells proliferation

Authors:
- Guo‑Ping Chen
- Xiao‑Qin Zhang
- Tao Wu
- Jie Han
- Dan Ye
View Affiliations

Affiliations: Department of Endocrinology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Department of Respirology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China, Institute of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: March 23, 2017 https://doi.org/10.3892/mmr.2017.6360
Pages: 3153-3160

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The proliferation of vascular smooth muscle cells (VSMCs) is one of the main features of atherosclerosis accelerated by hyperglycemia. Our previous studies found that farnesyl pyrophosphate synthase (FPPS, EC 2.5.1.10), an essential enzyme in the mevalonate pathway, was upregulated in aorta media from diabetic mice along with the process of atherosclerosis. However, the exact role of FPPS in high glucose‑induced proliferation of VSMCs is largely unclear. In our study, we found that alendronate (an FPPS inhibitor) attenuated diabetic accelerated atherosclerosis in vivo and suppressed high glucose‑induced VSMCs proliferation in vitro. Moreover, in aorta from streptozotocin (STZ)‑induced diabetic mice, 16‑week treatment of alendronate decreased the activation of small GTPase (Ras, RhoA, and Rac1), but had no effect on the expression of cystathionine γ‑lyase (CSE), the pivotal H2S‑producing enzyme. Meanwhile, in VSMCs cultured in high glucose‑containing media, alendronate remarkably decreased total CoQ content, increased the H2S level, depressed small GTPases (Ras, RhoA, and Rac1) activation, but yet had no effect on expression of CSE. In conclusion, FPPS inhibition by alendronate attenuated the high glucose‑induced proliferation of VSMCs both in vivo and in vitro, probably though depressing H2S metabolism and suppressing small GTPases (Ras, RhoA, and Rac1) activation.

View Figures

View References

1	Nickerson HD and Dutta S: Diabetic complications: Current challenges and opportunities. J Cardiovasc Transl Res. 5:375–379. 2012. View Article : Google Scholar : PubMed/NCBI
2	Schmidt AM: Recent highlights of ATVB: Diabetes mellitus. Arterioscler Thromb Vasc Biol. 34:954–958. 2014. View Article : Google Scholar : PubMed/NCBI
3	Porter KE and Riches K: The vascular smooth muscle cell: A therapeutic target in type 2 diabetes? Clin Sci. 125:167–182. 2013. View Article : Google Scholar : PubMed/NCBI
4	Gray SP and Jandeleit-Dahm K: The pathobiology of diabetic vascular complications-cardiovascular and kidney disease. J Mol Med. 92:441–452. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chait A and Bornfeldt KE: Diabetes and atherosclerosis: Is there a role for hyperglycemia? J Lipid Res. 50:(Suppl). S335–S339. 2009. View Article : Google Scholar : PubMed/NCBI
6	Rudijanto A: The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 39:86–93. 2007.PubMed/NCBI
7	Dhar MK, Koul A and Kaul S: Farnesyl pyrophosphate synthase: A key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development. N Biotechnol. 30:114–123. 2013. View Article : Google Scholar : PubMed/NCBI
8	Sun S and McKenna CE: Farnesyl pyrophosphate synthase modulations: A patent review (2006–2010). Expert Opin Ther Pat. 21:1433–1451. 2011. View Article : Google Scholar : PubMed/NCBI
9	Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
10	Buhaescu I and Izzedine H: Mevalonate pathway: A review of clinical and therapeutical implications. Clin Biochem. 40:575–584. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chen GP, Zhang XQ, Wu T, Li L, Han J and Du CQ: Alteration of mevalonate pathway in proliferated vascular smooth muscle from diabetic mice: Possible role in high-glucose-induced atherogenic process. J diabetes Res. 2015:3792872015. View Article : Google Scholar : PubMed/NCBI
12	Russell RG: Bisphosphonates: The first 40 years. Bone. 49:2–19. 2011. View Article : Google Scholar : PubMed/NCBI
13	Chen GP, Li L, Yang Y, Fu M, Yao L, Wu T, Zhang XQ and Hu SJ: Chronic inhibition of Farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats. Biochem Pharmacol. 80:1684–1689. 2010. View Article : Google Scholar : PubMed/NCBI
14	Mehrhof FB, Schmidt-Ullrich R, Dietz R and Scheidereit C: Regulation of vascular smooth muscle cell proliferation: Role of NF-kappaB revisted. Circ Res. 96:958–964. 2005. View Article : Google Scholar : PubMed/NCBI
15	Chen GP, Yao L, Lu X, Li L and Hu SJ: Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats. Acta Pharmacol Sin. 29:1181–1186. 2008. View Article : Google Scholar : PubMed/NCBI
16	Lang JK, Gohil K and Packer L: Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions. Anal Biochem. 157:106–116. 1986. View Article : Google Scholar : PubMed/NCBI
17	Zhu YZ, Wang ZJ, Ho P, Loke YY, Zhu YC, Huang SH, Tan CS, Whiteman M, Lu J and Moore PK: Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. J Appl Physiol (1985). 102:261–268. 2007. View Article : Google Scholar : PubMed/NCBI
18	Xu S, Liu Z and Liu P: Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis. Int J Cardiol. 172:313–317. 2014. View Article : Google Scholar : PubMed/NCBI
19	Vandiver M and Snyder SH: Hydrogen sulfide: A gasotransmitter of clinical relevance. J Mol Med (Berl). 90:255–263. 2012. View Article : Google Scholar : PubMed/NCBI
20	Gadalla MM and Synder SH: Hydrogen sulfide as a gasotransmitter. J Neurochem. 113:14–26. 2010. View Article : Google Scholar : PubMed/NCBI
21	Whiteman M, Le Trionnaire S, Chopra M, Fox B and Whatmore J: Emerging role of hydrogen sulfide in health and disease: Critical appraisal of biomarkers and pharmacological tools. Clin Sci. 121:459–488. 2011. View Article : Google Scholar : PubMed/NCBI
22	Mani S, Untereiner A, Wu L and Wang R: Hydrogen sulfide and the pathogenesis of atherosclerosis. Antioxid Redox Signal. 20:805–817. 2014. View Article : Google Scholar : PubMed/NCBI
23	Qiao W, Chaoshu T, Hongfang J and Junbao D: Endogenous hydrogen sulfide is involved in the pathogenesis of atherosclerosis. Biochem Biophys Res Commun. 396:182–186. 2010. View Article : Google Scholar : PubMed/NCBI
24	Elsey DJ, Fowkes RC and Baxter GF: Regulation of cardiovascular cell function by hydrogen sulfide (H(2)S). Cell Biochem Funct. 28:95–106. 2010. View Article : Google Scholar : PubMed/NCBI
25	Martelli A, Testai L, Marino A, Breschi MC, Da Settimo F and Calderone V: Hydrogen sulphide: Biopharmacological roles in the cardiovascular system and pharmaceutical perspectives. Curr Med Chem. 19:3325–3326. 2012. View Article : Google Scholar : PubMed/NCBI
26	Beltowski J and Jamroz-Wisniewska A: Modulation of H(2)S metabolism by statins: A new aspect of cardiovascular pharmacology. Antioxid Redox Signal. 17:81–94. 2012. View Article : Google Scholar : PubMed/NCBI
27	Chen J, Dai M and Wang Y: Paeonol inhibits proliferation of vascular smooth muscle cells stimulated by high glucose via Ras-Raf-ERK1/2 signaling pathway in coculture model. Evid Based Complement Alternat Med. 2014:4842692014. View Article : Google Scholar : PubMed/NCBI
28	Zhao Y, Liu J, Li L, Liu L and Wu L: Role of Ras/PKCzeta/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul Pept. 128:43–50. 2005. View Article : Google Scholar : PubMed/NCBI
29	Ishiko K, Sakoda T, Akagami T, Naka T, Doi T, Tsujino T, Masuyama T and Ohyanagi M: Hyperglycemia induced cell growth and gene expression via the serum response element through RhoA and Rho-kinase in vascular smooth muscle cells. Prep Biochem Biotechnol. 40:139–151. 2010. View Article : Google Scholar : PubMed/NCBI
30	Sawada N, Li Y and Liao JK: Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol. 10:116–121. 2010. View Article : Google Scholar : PubMed/NCBI
31	Zhu LH, Wang L, Wang D, Jiang H, Tang QZ, Yan L, Bian ZY, Wang XA and Li H: Puerarin attenuates high-glucose and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling. Free Radic Biol Med. 48:471–482. 2010. View Article : Google Scholar : PubMed/NCBI
32	McTaggart SJ: Isoprenylated proteins. Cell Mol Life Sci. 63:255–267. 2006. View Article : Google Scholar : PubMed/NCBI
33	Roskoski R Jr: Protein prenylation: A pivotal posttranslational process. Biochem Biophys Res Commun. 303:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
34	Casey PJ: Protein lipidation in cell signaling. Science. 268:221–225. 1995. View Article : Google Scholar : PubMed/NCBI
35	Ylitalo R, Mönkkönen J, Urtti A and Ylitalo P: Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med. 127:200–206. 1996. View Article : Google Scholar : PubMed/NCBI
36	Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Sisto T, Lähteenmäki T, Ylitalo P and Pörsti I: Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol. 83:125–131. 1998. View Article : Google Scholar : PubMed/NCBI